Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 12, 2021

SELL
$23.37 - $32.13 $359,360 - $494,063
-15,377 Closed
0 $0
Q2 2021

Aug 12, 2021

SELL
$18.78 - $25.15 $14,404 - $19,290
-767 Reduced 4.75%
15,377 $377,000
Q1 2021

May 12, 2021

BUY
$18.21 - $23.2 $62,715 - $79,900
3,444 Added 27.12%
16,144 $322,000
Q4 2020

Feb 12, 2021

BUY
$15.39 - $22.1 $140,049 - $201,110
9,100 Added 252.78%
12,700 $253,000
Q3 2020

Nov 12, 2020

BUY
$16.16 - $20.66 $58,176 - $74,376
3,600 New
3,600 $60,000
Q1 2020

May 13, 2020

SELL
$13.06 - $21.24 $3,918 - $6,371
-300 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$17.29 - $21.74 $2 Million - $2.51 Million
-115,576 Reduced 99.74%
300 $6,000
Q3 2019

Nov 12, 2019

SELL
$19.51 - $24.28 $85,902 - $106,904
-4,403 Reduced 3.66%
115,876 $2.28 Million
Q2 2019

Aug 07, 2019

BUY
$21.47 - $37.33 $114,671 - $199,379
5,341 Added 4.65%
120,279 $2.66 Million
Q1 2019

May 13, 2019

SELL
$28.4 - $36.49 $27,945 - $35,906
-984 Reduced 0.85%
114,938 $4.1 Million
Q4 2018

Feb 12, 2019

SELL
$27.94 - $44.61 $6,202 - $9,903
-222 Reduced 0.19%
115,922 $3.42 Million
Q3 2018

Nov 13, 2018

SELL
$38.6 - $46.12 $7.58 Million - $9.05 Million
-196,274 Reduced 62.82%
116,144 $4.93 Million
Q2 2018

Aug 10, 2018

BUY
$40.56 - $51.36 $143,339 - $181,506
3,534 Added 1.14%
312,418 $12.9 Million
Q1 2018

May 11, 2018

SELL
$53.61 - $67.26 $4,610 - $5,784
-86 Reduced 0.03%
308,884 $17.9 Million
Q4 2017

Feb 09, 2018

SELL
$47.69 - $55.39 $8,441 - $9,804
-177 Reduced 0.06%
308,970 $16.9 Million
Q3 2017

Nov 13, 2017

BUY
$49.16 - $54.45 $15.2 Million - $16.8 Million
309,147
309,147 $15.7 Million

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.61B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Mitsubishi Ufj Trust & Banking Corp Portfolio

Follow Mitsubishi Ufj Trust & Banking Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitsubishi Ufj Trust & Banking Corp, based on Form 13F filings with the SEC.

News

Stay updated on Mitsubishi Ufj Trust & Banking Corp with notifications on news.